Navigation Links
ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
Date:4/17/2008

Three Developmental Compounds Show Early Promise

MONTREAL, April 17 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced results of three compounds in preclinical studies for prostate and pancreatic cancer at the American Association for Cancer Research ("AACR") Annual Meeting 2008 being held in San Diego this week.

Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessions as follows:

Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data on PBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayed significant antitumor activity in human prostate cancer both in vitro and in vivo. The in vivo study demonstrated a significant reduction in tumor volume both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01).

Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, presented preclinical data on the PBI-0110 alone and in combination with gemcitabine in intradermal and orthotopic pancreatic cancer. The study showed that PBI-0110 alone significantly inhibited pancreatic tumor growth in mouse models by as much as 58 percent (p < 0.05) after 44 days. The study also demonstrated a dose dependent inhibition of tumor growth, with the 400mg/kg dose being the most effective, inhibiting growth by nearly 40 percent after 25 days (p < 0.05). Combination therapy of 100mg/kg PBI-0110 and gemcitabine demonstrated similar efficacy. Finally, the study demonstrated increased survival in mice that received the combination therapy of PBI-0110 200mg/kg and gemcitabine.

Finally, Dr. Brigitte Grouix, ProMetic research scientist, presented data on PBI-1308, which demonstrated a reduction of inflammation and cancer cell proliferation through inhibition of NF-kappaB in prostate cancer and inhibition of TNF-alpha, and inflammatory cytokine.

"We continue to be very proud of the progress our compounds are making in early-stage cance
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
3. ProMetic provides business update - Over $35 million worth of business secured in January
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
7. Prometic to present at the American Chemical Society
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... Columbia, Pa. (PRWEB) May 29, 2015 ... Thermal Product Solutions with a request to design ... remove excess moisture from prescription medications being produced ... custom solution that includes a robotic gantry, heat-saving ... positions and dries trays of 3D-printed pills to ...
(Date:5/29/2015)... , May 29, 2015  Caris Life ... on fulfilling the promise of precision medicine, today ... that demonstrate the clinical utility of Caris Molecular ... profiling service, in helping to identify targeted treatment ... In each of the studies, results of which ...
(Date:5/29/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... New York City . The presentation ... Thursday, June 4, 2015, at 11:00 AM Eastern Time, and ...
Breaking Biology Technology:Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... , NEW YORK, Dec. 4 Stemline Therapeutics, Inc. ... agents, SL-401 and SL-501, in both in vitro and ... for poster presentation at the upcoming 51st Annual Meeting of the ... from December 5-8, 2009. The poster will be presented by Stemline,s ...
... , HOUSTON, Dec. 3 ... updated its facility to offer patients a second surgical option, ... that it currently performs. The first sleeve gastrectomy procedure at the ... on October 20, 2009. The patient is reported as doing ...
... , ... (OTC Bulletin Board: ACCP), today provided ... FDA approved treatment for oral mucositis, a debilitating side effect ... Access, partner, SpePharm, in six European countries, including the UK, ...
Cached Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Center for Molecular Medicine (MDC) Berlin-Buch have gained new ... Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit ... damage within seconds, activates the transcription factor NF-kappaB, a ... program, which blocks programmed cell death. The activation of ...
... Andrews in the UK have found that the color of ... appear, and have found that diet may be crucial to ... in the December issue of Springer,s International Journal of ... of 54 Caucasian participants of both sexes were asked to ...
... While mothers have known that feeding their kids milk builds ... Institute at Intermountain Medical Center in Salt Lake City suggests ... as well and that inadequate levels of the vitamin ... and death, even among people who,ve never had heart disease. ...
Cached Biology News:How cells tolerate DNA damage -- start signal for cell survival program identified 2How cells tolerate DNA damage -- start signal for cell survival program identified 3Skin color gives clues to health 2New study links vitamin D deficiency to cardiovascular disease and death 2New study links vitamin D deficiency to cardiovascular disease and death 3
... Detection System is intended for use in ... by an in-house validated method for in ... target of interest. • ... a hybridization capture assay designed to detect ...
... maximum packaging efficiencies of cDNA and genomic DNA ... a test insert with Novagen's l vector arms, ... 10^8 pfu/g ligated l control DNA) are typically ... use; simply add up to 5 g of ...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: